La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial
SAN DIEGO, March 20, 2007 /PRNewswire-FirstCall/ -- La JollaPharmaceutical Company today announced updated interim antibodyreduction data for the Phase 3 trial of Riquent(R) (abetimussodium), its drug candidate for systemic lupus erythematosus("lupus" or "SLE"). The updated analyses reinforce the previousconclusion that there is a definitive and significant dose responsebetween the 100 m...La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
Data Support Ability of Higher Doses to Further Reduce Antibodiesto Double-Stranded DNA SAN DIEGO, March 08, 2007 /PRNewswire-FirstCall/ -- La JollaPharmaceutical Company today announced positive interim antibodyresults from its ongoing double-blind, placebo-controlledrandomized Phase 3 trial of Riquent(R) (abetimus sodium), its drugcandidate for systemic lupus erythematosus ("lupus" or "...